On March 11, 2019, Dong-A ST (Chairman Eom Dae-sig) announced that the recent clinical trial of Zydena, an erectile dysfunction treatment, showed an improvement of post-micturition dribble (PMD).

The trial was conducted to determine the effectiveness of Udenafil on PMD in men via the administration of Zydena (generic name: Udenafil), an erectile dysfunction treatment. 138 male patients were randomized to receive 75mg of Zydena or a placebo for 12 weeks. The comparative study was conducted at four medical institutions over a period of 18 months from December 2014 to May 2016.

PMD, commonly found in middle-aged men, is a symptom of discomfort caused by the leakage of urine left in the urethra after urination. It occurs when the urine remaining in the urethra does not completely drain due to weakened muscles in the urethra or when the bladder does not contract enough to discharge a small amount of urine.

Of the 138 patients who participated in the trial, 59 (42.8%) men experienced PMD once out of every three urinations, 45 (32.6%) men experienced PMD twice out of every three urinations, and 34 (24.6%) men experienced PMD three times out of every three urinations. Meanwhile, 89 (65.4%) men pointed out that PMD causes moderate to serious discomfort in their daily lives.

In the clinical trial, the use of Zydena 75mg in patients with PMD showed a significant improvement of PMD symptoms, including a reduction in PMD frequency and the symptom score compared to placebo.

An official of Dong-A ST said, “This clinical trial confirms that Zydena can be an effective way of treating PMD. We will continue to accumulate data on its safety and efficacy for patients suffering from PMD.”